The Alzheimer's disease risk factor INPP5D restricts neuroprotective microglial responses in amyloid beta‐mediated pathology
Alzheimer's & Dementia · 2023-11 · 19 (11) · 4908-4921
DOI: 10.1002/alz.13089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 15.04.2023. Verfasst von Joshua D Samuels und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia (UVA), Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIBIB NIH HHS, NINDS NIH HHS, NIGMS NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Introduction
Mutations in INPP5D , which encodes for the SH2‐domain‐containing inositol phosphatase SHIP‐1, have recently been linked to an increased risk of developing late‐onset Alzheimer's disease. While INPP5D expression is almost exclusively restricted to microglia in the brain, little is known regarding how SHIP‐1 affects neurobiology or neurodegenerative disease pathogenesis.
Methods
We generated and investigated 5xFAD Inpp5d fl/fl Cx3cr1 Ert2Cre mice to ascertain the function of microglial SHIP‐1 signaling in response to amyloid beta (Aβ)‐mediated pathology.
Results
SHIP‐1 deletion in microglia led to substantially enhanced recruitment of microglia to Aβ plaques, altered microglial gene expression, and marked improvements in neuronal health. Further, SHIP‐1 loss enhanced microglial plaque containment and Aβ engulfment when compared to microglia from Cre‐negative 5xFAD Inpp5d fl/fl littermate controls.
Discussion
These results define SHIP‐1 as a pivotal regulator of microglial responses during Aβ‐driven neurological disease and suggest that targeting SHIP‐1 may offer a promising strategy to treat Alzheimer's disease. Highlights Inpp5d deficiency in microglia increases plaque‐associated microglia numbers. Loss of Inpp5d induces activation and phagocytosis transcriptional pathways. Plaque encapsulation and engulfment by microglia are enhanced with Inpp5d deletion. Genetic ablation of Inpp5d protects against plaque‐induced neuronal dystrophy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia (UVA), Charlottesville, Virginia, USA.
- Neuroscience Graduate Program, University of Virginia (UVA), Charlottesville, Virginia, USA.
- Department of Biomedical Engineering, University of Virginia (UVA), Charlottesville, Virginia, USA.
- Brain Immunology and Glia Training Program, University of Virginia (UVA), Charlottesville, Virginia, USA.
- Molecular Physiology and Biological Physics Graduate Program, University of Virginia (UVA), Charlottesville, Virginia, USA.
- Biotechnology Training Program, University of Virginia (UVA), Charlottesville, Virginia, USA.
ORCID-Profile: John R Lukens
Förderung
- NIBIB NIH HHS
- NINDS NIH HHS
- NIGMS NIH HHS
- NIA NIH HHS
Zitieren
APA
Samuels, J. D., Moore, K. A., Ennerfelt, H. E., Johnson, A. M., Walsh, A. E., Price, R. J., & Lukens, J. R. (2023). The Alzheimer's disease risk factor INPP5D restricts neuroprotective microglial responses in amyloid beta‐mediated pathology. Alzheimer's & Dementia, 19(11), 4908-4921. https://doi.org/10.1002/alz.13089
Vancouver
Samuels JD, Moore KA, Ennerfelt HE, Johnson AM, Walsh AE, Price RJ, et al. The Alzheimer's disease risk factor INPP5D restricts neuroprotective microglial responses in amyloid beta‐mediated pathology. Alzheimer's & Dementia. 2023;19(11):4908-4921. doi:10.1002/alz.13089
BibTeX
@article{Samuels2023,
author = {Samuels, Joshua D and Moore, Katelyn A and Ennerfelt, Hannah E and Johnson, Alexis M and Walsh, Adeline E and Price, Richard J and Lukens, John R},
title = {The Alzheimer's disease risk factor INPP5D restricts neuroprotective microglial responses in amyloid beta‐mediated pathology},
journal = {Alzheimer's & Dementia},
year = {2023},
volume = {19},
number = {11},
pages = {4908--4921},
doi = {10.1002/alz.13089}
}
EUVIMED